Short-term effect of infliximab is reflected in the clot lysis profile of patients with inflammatory bowel disease: A prospective study

Inflammatory Bowel Diseases

Volumn 21, Issue 3, 2015, Pages 570-578

  Bollen, Lize ^a   Casteele, Niels Vande ^a   Peeters, Miet ^a   Bessonov, Kyrylo ^b   Van Steen, Kristel ^b   Rutgeerts, Paul ^c   Ferrante, Marc ^c   Hoylaerts, Marc F ^d   Vermeire, Severine ^c   Gils, Ann ^a  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

fibrinolysis; hemostasis; inflammatory bowel diseases; infliximab; venous thromboembolism

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; INFLIXIMAB; METHOTREXATE; GASTROINTESTINAL AGENT;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BODY MASS; COMPARATIVE STUDY; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EUGLOBULIN LYSIS TEST; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; IMMUNOASSAY; INFLAMMATORY BOWEL DISEASE; INFUSION RELATED REACTION; INVESTIGATIVE PROCEDURES; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SHORT COURSE THERAPY; SMOKING; ADOLESCENT; BLOOD; CASE CONTROL STUDY; COMPLICATION; CROHN DISEASE; DRUG EFFECTS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; THROMBOSIS; ULCERATIVE COLITIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; FIBRINOLYSIS; GASTROINTESTINAL AGENTS; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; THROMBOSIS; YOUNG ADULT;

EID: 84923423503     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000301     Document Type: Article

References (30)

1. White RH. The epidemiology of venous thromboembolism. Circulation. 2003; 107: I4-I8.
2. Bernstein CN, Blanchard JF, Houston DS, et al. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost. 2001; 85: 430-434.
3. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010; 375: 657-663.
4. Fumery M, Xiaocang C, Dauchet L, et al. Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-Analysis of observational studies. J Crohns Colitis. 2014; 8: 469-479.
5. Murthy SK, Nguyen GC. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am J Gastroenterol. 2011; 106: 713-718.
6. Nguyen GC, Bernstein CN, Bitton A, et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology. 2014; 146: 835-848.e836.
7. Papa A, Gerardi V, Marzo M, et al. Venous thromboembolism in patients with inflammatory bowel disease: focus on prevention and treatment. World J Gastroenterol. 2014; 20: 3173-3179.
8. Ladenvall C, Gils A, Jood K, et al. Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation. Arterioscler Thromb Vasc Biol. 2007; 27: 955-962.
9. Lisman T, de Groot PG, Meijers JC, et al. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood. 2005; 105: 1102-1105.
10. Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis. 2010; 4: 355-366.
11. Meissenheimer LM, Verbeke K, Declerck PJ, et al. Quantitation of Vervet monkey (Chlorocebus aethiops) plasminogen activator inhibitor-1 in plasma and platelets. Thromb Haemost. 2006; 95: 902-903.
12. Declerck PJ, Alessi MC, Verstreken M, et al. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood. 1988; 71: 220-225.
13. Declerck PJ, Verstreken M, Collen D. An Immunofunctional assay for active plasminogen activator inhibitor-1 (PAI-1). Fibrinolysis. 1988; 2 (suppl 2): 77-78.
14. Ceresa E, Brouwers E, Peeters M, et al. Development of ELISAs measuring the extent of TAFI activation. Arterioscler Thromb Vasc Biol. 2006; 26: 423-428.
15. Vande Casteele N, Buurman DJ, Sturkenboom MG, et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther. 2012; 36: 765-771.
16. Saibeni S, Bottasso B, Spina L, et al. Assessment of thrombin-Activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. Am J Gastroenterol. 2004; 99: 1966-1970.
17. Koutroubakis IE, Sfiridaki A, Tsiolakidou G, et al. Plasma thrombinactivatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2008; 20: 912-916.
18. Leurs J, Nerme V, Sim Y, et al. Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a thresholddependent mechanism. J Thromb Haemost. 2004; 2: 416-423.
19. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys. Gut. 2006; 55: 426-431.
20. Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008; 103: 2272-2280.
21. Papay P, Miehsler W, Tilg H, et al. Clinical presentation of venous thromboembolism in inflammatory bowel disease. J Crohns Colitis. 2013; 7: 723-729.
22. Petitpain N, Gambier N, Wahl D, et al. Arterial and venous thromboembolic events during anti-TNF therapy: a study of 85 spontaneous reports in the period 2000-2006. Biomed Mater Eng. 2009; 19: 355-364.
23. Korswagen LA, Bartelds GM, Krieckaert CL, et al. Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum. 2011; 63: 877-883.
24. Davies R, Galloway JB, Watson KD, et al. Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011; 70: 1831-1834.
25. Ingegnoli F, Fantini F, Griffini S, et al. Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis. Clin Exp Rheumatol. 2010; 28: 254-257.
26. Bessissow T, Renard M, Hoffman I, et al. Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy. Aliment Pharmacol Ther. 2012; 36: 312-323.
27. Higgins PD, Skup M, Mulani PM, et al. Increased risk of venous thromboembolic events with corticosteroid vs biologic therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014.
28. Alkim H, Ayaz S, Alkim C, et al. Continuous active state of coagulation system in patients with nonthrombotic inflammatory bowel disease. Clin Appl Thromb Hemost. 2011; 17: 600-604.
29. Oussalah A, Gueant JL, Peyrin-Biroulet L. Meta-Analysis: hyperhomocysteinaemia in inflammatory bowel diseases. Aliment Pharmacol Ther. 2011; 34: 1173-1184.
30. Saibeni S, Saladino V, Chantarangkul V, et al. Increased thrombin generation in inflammatory bowel diseases. Thromb Res. 2010; 125: 278-282.